Document is current
Any future updates will be listed below
-
Authors
Kapahnke, Karl https://orcid.org/0009-0004-2178-0680
Plenge, Thomas
Klaus, Tabea https://orcid.org/0009-0004-1629-5664
Gupta, Manoj K. https://orcid.org/0000-0003-1558-9471
Anand, Disha
Önder, Tamer T. https://orcid.org/0000-0002-2372-9158
Perner, Birgit
Schnöder, Tina M.
Thol, Felicitas R. https://orcid.org/0000-0001-5848-6152
Damm, Frederik https://orcid.org/0000-0001-5553-1173
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
Perner, Florian https://orcid.org/0000-0003-1010-3321
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (PE 3217/2-1, PN: 528168324, PE 3217/4-1, PN: 517204983, HE6233/16-1, PN: 517204983, HE6233/4-2, PN: 320028127, DA 1787/6-1)
Else Kröner-Fresenius-Stiftung (2021-EKEA.111)
José Carreras Leukämie-Stiftung (José Carreras-DGHO stipend 2022/23)
Deutsche Krebshilfe (70113643)
- License Information
-
More Information
Article History
Received: 6 January 2025
Revised: 24 June 2025
Accepted: 21 July 2025
First Online: 8 August 2025
Competing interests
: FHH is a consultant for BMS/Celgene, AOP, Novartis, CTI, Janssen, AbbVie, GSK, Merck, CTI, Kartos, Telios and Silence Therapeutics and received research funding from: Novartis, BMS/Celgene and CTI. FP received travel support from Syndax Pharmaceuticals and CHARM Therapeutics. FD reports personal fees from AbbVie, Amgen, AstraZeneca, BeiGene, Gilead, Incyte, Johnson&Johnson, Novartis, Roche, and SOBI. All other authors have no conflicts of interest to disclose.
: All experimental methods and procedures were performed in accordance with the relevant guidelines and regulations. The work with primary human specimens was approved by the institutional review board of Hannover Medical School (ethical votes 936/2011 and 3432-2016) and written informed consent was obtained according to the Declaration of Helsinki.
